Sökning: onr:"swepub:oai:DiVA.org:uu-498884" >
Survival by First-l...
-
Weibull, Caroline E.Karolinska Institutet
(författare)
Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients : A National Population-based Study in Sweden
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
-
Wolters Kluwer,2023
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-498884
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498884URI
-
https://doi.org/10.1097/HS9.0000000000000838DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:152008248URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
In follicular lymphoma (FL), progression of disease <= 24 months (POD24) has emerged as an important prognostic marker for overall survival (OS). We aimed to investigate survival more broadly by timing of progression and treatment in a national population-based setting. We identified 948 stage II-IV indolent FL patients in the Swedish Lymphoma Register diagnosed 2007-2014 who received first-line systemic therapy, followed through 2020. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated by first POD at any time during follow-up using Cox regression. OS was predicted by POD using an illness-death model. During a median follow-up of 6.1 years (IQR: 3.5-8.4), 414 patients experienced POD (44%), of which 270 (65%) occurred <= 24 months. POD was represented by a transformation in 15% of cases. Compared to progression-free patients, POD increased all-cause mortality across treatments, but less so among patients treated with rituximab(R)-single (HR = 4.54, 95% CI: 2.76-7.47) than R-chemotherapy (HR = 8.17, 95% CI: 6.09-10.94). The effect of POD was similar following R-CHOP (HR = 8.97, 95% CI: 6.14-13.10) and BR (HR = 10.29, 95% CI: 5.60-18.91). The negative impact of POD on survival remained for progressions up to 5 years after R-chemotherapy, but was restricted to 2 years after R-single. After R-chemotherapy, the 5-year OS conditional on POD occurring at 12, 24, and 60 months was 34%, 46%, and 57% respectively, versus 78%, 82%, and 83% if progression-free. To conclude, POD before but also beyond 24 months is associated with worse survival, illustrating the need for individualized management for optimal care of FL patients.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Wasterlid, ToveKarolinska Institutet
(författare)
-
Wahlin, Bjorn EngelbrektKarolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Unit Hematol, Stockholm, Sweden.
(författare)
-
Andersson, Per-OlaSahlgrens Univ Hosp, Sect Hematol & Coagulat, Gothenburg, Sweden.
(författare)
-
Ekberg, SaraKarolinska Institutet
(författare)
-
Lockmer, SandraKarolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Unit Hematol, Stockholm, Sweden.
(författare)
-
Enblad, GunillaUppsala universitet,Institutionen för immunologi, genetik och patologi(Swepub:uu)gunienbl
(författare)
-
Crowther, Michael J.Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.;Red Door Analyt, Stockholm, Sweden.
(författare)
-
Kimby, EvaKarolinska Institutet
(författare)
-
Smedby, Karin E.Karolinska Inst, Dept Med Solna, Clin Epidemiol Div, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.
(författare)
-
Karolinska InstitutetKarolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med Huddinge, Unit Hematol, Stockholm, Sweden.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:HemaSphere: Wolters Kluwer7:32572-9241
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Weibull, Carolin ...
-
Wasterlid, Tove
-
Wahlin, Bjorn En ...
-
Andersson, Per-O ...
-
Ekberg, Sara
-
Lockmer, Sandra
-
visa fler...
-
Enblad, Gunilla
-
Crowther, Michae ...
-
Kimby, Eva
-
Smedby, Karin E.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
HemaSphere
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet